J.P. Morgan Securities Co., Ltd. raised Pharmaceutical Biotech's rating to an overrated rating. Analyst Yang Huang's previous rating was neutral. The target price is HK$20, which is expected to increase 24% from the latest closing price.

Zhitongcaijing · 01/07 18:33
J.P. Morgan Securities Co., Ltd. raised Pharmaceutical Biotech's rating to an overrated rating. Analyst Yang Huang's previous rating was neutral. The target price is HK$20, which is expected to increase 24% from the latest closing price.